Sima Stein, MD
Pediatrics · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 3
- 2 carriers
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
3 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Stein’s office at (408) 292-0100 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A55498 · Current
Licensed to practise in California · since 1996 · expires 2028-01-31 · Second Moscow N. I. Pirogov State Medical Institute.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$14,865 in 2024
Medicaid paid $14,865 for 1,384 billed services this clinician did in 2024, up to 71 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Developmental screening | 330 | $9,428 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 65 | $1,443 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 73 | $1,322 |
| Pure tone audiometry (threshold); air only | 161 | $1,149 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 148 | $1,011 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 25 | $208 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 13 | $115 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 16 | $89 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 14 | $89 |
| Brief emotional/behavioral assessment (eg, depression inventory, attention-deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument | 13 | $11 |
| Medical nutrition therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes | 55 | $0 |
| Short return visit (20+ min) | 307 | $0 |
| 2024 | 1,384 | 15 | 71 | $14,865 |
| 2023 | 4,666 | 21 | 156 | $93,232 |
| 2022 | 3,917 | 19 | 123 | $75,536 |
| 2021 | 3,018 | 15 | 75 | $59,327 |
| 2020 | 2,441 | 21 | 96 | $54,549 |
| 2019 | 3,363 | 21 | 79 | $66,694 |
| 2018 | 2,862 | 21 | 93 | $54,101 |
See the largest Medicaid services in earlier years
2023
| Developmental screening | 968 | $42,505 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 275 | $9,157 |
| Pure tone audiometry (threshold); air only | 628 | $8,054 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 217 | $7,256 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 502 | $7,018 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 209 | $6,382 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | 71 | $4,279 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 106 | $4,104 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 202 | $1,458 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 128 | $1,042 |
| Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | 58 | $629 |
| Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 68 | $546 |
2022
| Developmental screening | 845 | $36,908 |
| Pure tone audiometry (threshold); air only | 583 | $7,535 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 226 | $7,363 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 491 | $6,753 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 212 | $6,635 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 109 | $3,226 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 74 | $3,186 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 143 | $1,161 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib-HepB), for intramuscular use | 15 | $960 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 104 | $683 |
| Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use | 42 | $367 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 28 | $218 |
2021
| Developmental screening | 663 | $30,390 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 182 | $6,187 |
| Pure tone audiometry (threshold); air only | 435 | $5,445 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 170 | $5,194 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 390 | $3,556 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 92 | $2,428 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 29 | $1,426 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 188 | $1,364 |
| Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | 118 | $1,031 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 134 | $975 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use | 67 | $556 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 46 | $340 |
2020
| Developmental screening | 563 | $27,664 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 207 | $6,853 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 173 | $5,841 |
| Pure tone audiometry (threshold); air only | 416 | $5,579 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 298 | $2,593 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 53 | $2,529 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 106 | $898 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 38 | $577 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 53 | $444 |
| Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use | 36 | $321 |
| Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | 21 | $318 |
| Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use | 21 | $214 |
2019
| Developmental screening | 742 | $33,523 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 285 | $8,491 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 193 | $6,430 |
| Pure tone audiometry (threshold); air only | 509 | $6,028 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 431 | $3,506 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 92 | $3,004 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 273 | $2,165 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 26 | $877 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 73 | $614 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 51 | $406 |
| Varicella virus vaccine (VAR), live, for subcutaneous use | 41 | $274 |
| DIPHTH TETANUS TOX ACELL PERTUSSIS VACC<7 YR IM | 30 | $248 |
2018
| Developmental screening | 701 | $28,762 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 285 | $9,795 |
| Pure tone audiometry (threshold); air only | 339 | $3,456 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 90 | $3,157 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 274 | $2,337 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year) | 68 | $2,081 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 27 | $877 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 109 | $813 |
| Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use | 88 | $756 |
| Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use | 53 | $473 |
| Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use | 51 | $407 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 44 | $284 |
Money from drug and device companies
$255 in 2025
| 2025 | 9 | 12 | None | $255 |
| 2024 | 6 | 9 | None | $208 |
| 2023 | 4 | 5 | None | $100 |
| 2022 | 7 | 13 | None | $231 |
| 2021 | 7 | 18 | None | $304 |
| 2020 | 3 | 13 | None | $214 |
| 2019 | 4 | 6 | None | $89 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Prevnar 20 | $63 | 4 payments
|
| Sanofi-Aventis U.S. | Tzield | $35 | 1 payment
|
| Seqirus USA | Flucelvax | $34 | 1 payment
|
| Sanofi Pasteur | Beyfortus | $29 | 1 payment
|
| Merck Sharp & Dohme | Gardasil 9 | $23 | 1 payment
|
| Verrica Pharmaceuticals | Ycanth | $23 | 1 payment
|
See all 12 published payments
| Ultragenyx Pharmaceutical | Meals · 2025-11-11 | Dojolvi | $17 |
| Pfizer | Meals · 2025-10-22 | Prevnar 20 | $17 |
| Sanofi Pasteur | Meals · 2025-10-15 | Beyfortus | $29 |
| Pfizer | Meals · 2025-09-23 | Prevnar 20 | $15 |
| Merck Sharp & Dohme | Meals · 2025-07-24 | Gardasil 9 | $23 |
| Verrica Pharmaceuticals | Meals · 2025-07-10 | Ycanth | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-13 | Fasenra | $18 |
| Pfizer | Meals · 2025-05-08 | Prevnar 20 | $16 |
| Pfizer | Meals · 2025-02-27 | Prevnar 20 | $15 |
| Sanofi-Aventis U.S. | Meals · 2025-02-27 | Tzield | $35 |
| Seqirus USA | Meals · 2025-01-28 | Flucelvax | $34 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-08 | Neffy | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $208
| Sanofi-Aventis U.S. | Tzield | $88 | 3 payments
|
| Pfizer | Prevnar 20 | $33 | 2 payments
|
| Merck Sharp & Dohme | Gardasil | $31 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $24 | 1 payment
|
| Genzyme | Dupixent | $18 | 1 payment
|
| Cranial Technologies | Doc Band | $14 | 1 payment
|
2023: $100
| Merck Sharp & Dohme | Rotateq | $31 | 1 payment
|
| Pfizer | Paxlovid | $30 | 2 payments
|
| ALK-Abello | Odactra | $21 | 1 payment
|
| Seqirus USA | Flucelvax Quadrivalent | $19 | 1 payment
|
2022: $231
| Cognoa | Canvas Dx | $72 | 3 payments
|
| Pfizer | Prevnar 13 | $39 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Flumist | $35 | 2 payments
|
| Seqirus USA | Flucelvax Quadrivalent | $29 | 2 payments
|
| ALK-Abello | Grastek | $26 | 1 payment
|
| Sanofi Pasteur | Vaxelis | $17 | 1 payment
|
| Cranial Technologies | Doc Band | $13 | 1 payment
|
2021: $304
| Pfizer | Prevnar 13 | $191 | 12 payments
|
| ALK-Abello | Otiprio | $22 | 1 payment
|
| Merck Sharp & Dohme | Gardasil 9 | $21 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $20 | 1 payment
|
| kaleo | Auvi-Q | $19 | 1 payment
|
| Sanofi Pasteur | Menquadfi | $19 | 1 payment
|
| Qiagen | Quantiferon-Tb Gold Plus | $13 | 1 payment
|
2020: $214
| Pfizer | Prevnar 13 | $176 | 11 payments
|
| ALK-Abello | Odactra | $25 | 1 payment
|
| Cranial Technologies | Doc Band | $13 | 1 payment
|
2019: $89
| Kaleo | Auvi-Q | $38 | 2 payments
|
| Pfizer | Prevnar - 13 | $25 | 2 payments
|
| Sanofi Pasteur | Adacel | $14 | 1 payment
|
| GlaxoSmithKline | Benlysta | $13 | 1 payment
|
Professional record
- NPI
- 1427134832
- Licence
- CA A55498California A55498: Current · expires 2028-01-31
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A554980
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 105 N Bascom Ave #102, San Jose, CA, 95128
- NPI first listed
- 2006-10-27
- NPI last updated
- 2008-11-05
This is when the NPI record was last certified, not a medical board exam.